IQVIA Holdings Inc. $IQV Shares Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 137,065 shares of the medical research company’s stock after acquiring an additional 3,250 shares during the quarter. Jefferies Financial Group Inc. owned approximately 0.08% of IQVIA worth $30,896,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Associated Banc Corp raised its holdings in shares of IQVIA by 3.0% in the fourth quarter. Associated Banc Corp now owns 176,163 shares of the medical research company’s stock worth $39,709,000 after acquiring an additional 5,205 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of IQVIA by 18.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 3,599 shares of the medical research company’s stock worth $811,000 after acquiring an additional 558 shares during the last quarter. Cumberland Partners Ltd raised its holdings in shares of IQVIA by 676.9% in the fourth quarter. Cumberland Partners Ltd now owns 12,718 shares of the medical research company’s stock worth $2,867,000 after acquiring an additional 11,081 shares during the last quarter. Lloyd Advisory Services LLC. acquired a new position in shares of IQVIA in the fourth quarter worth $44,000. Finally, Evoke Wealth LLC raised its holdings in shares of IQVIA by 9.5% in the fourth quarter. Evoke Wealth LLC now owns 2,234 shares of the medical research company’s stock worth $504,000 after acquiring an additional 193 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Evercore reiterated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Jefferies Financial Group dropped their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Citigroup dropped their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Finally, JPMorgan Chase & Co. dropped their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $225.69.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $168.28 on Friday. The firm has a market capitalization of $28.09 billion, a PE ratio of 20.85, a P/E/G ratio of 1.61 and a beta of 1.18. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The business has a 50-day moving average of $169.72 and a two-hundred day moving average of $197.56. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its Board of Directors has approved a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.